African histoplasmosis

African histoplasmosis
Synonyms	Histoplasmosis capsulati africana
Pronounce	N/A
Specialty	N/A
Symptoms	Skin lesions, lymphadenopathy, fever, cough, weight loss
Complications	Chronic pulmonary disease, disseminated disease
Onset	Variable
Duration	Chronic
Types	N/A
Causes	Fungal infection by Histoplasma capsulatum var. duboisii
Risks	Immunocompromised state, HIV/AIDS, exposure to bird or bat droppings
Diagnosis	Culture, histopathology, serology
Differential diagnosis	Tuberculosis, leprosy, sarcoidosis, cutaneous leishmaniasis
Prevention	Avoidance of exposure to contaminated environments
Treatment	Antifungal medication such as itraconazole, amphotericin B
Medication	N/A
Prognosis	Variable, depends on immune status and treatment
Frequency	Endemic in Sub-Saharan Africa
Deaths	N/A

African Histoplasmosis is a fungal infection caused by Histoplasma capsulatum var. duboisii, a variant of the fungus Histoplasma capsulatum which is endemic to certain parts of Africa. Unlike the more common form of histoplasmosis found in the Americas, which primarily affects the lungs, African histoplasmosis often involves the skin, bones, and other organs.

Etiology

African histoplasmosis is caused by the fungal organism Histoplasma capsulatum var. duboisii. The fungus thrives in soil enriched with bat or bird droppings. Infection occurs when spores are inhaled, although direct inoculation through the skin has been reported.

Epidemiology

This disease is predominantly found in Central and West Africa, with cases reported in countries such as Nigeria, Democratic Republic of Congo, and Ghana. It affects individuals of all ages but has a higher incidence in males and rural populations, likely due to increased exposure to the endemic areas.

Clinical Manifestations

The clinical presentation of African histoplasmosis can vary significantly. It often presents with chronic skin lesions that may ulcerate. Lymphadenopathy, osteolytic bone lesions, and respiratory symptoms may also occur. Disseminated disease is not uncommon and can affect the liver, spleen, and central nervous system.

Diagnosis

Diagnosis of African histoplasmosis is challenging and relies on a combination of clinical suspicion, epidemiological context, histopathological examination, and culture of the fungus from clinical specimens. Serological tests and molecular methods such as PCR can also aid in diagnosis but may not be readily available in endemic regions.

Treatment

The treatment of choice for African histoplasmosis is the antifungal medication itraconazole, with amphotericin B used in severe or disseminated cases. The duration of treatment varies depending on the severity and site of infection but typically lasts for several months.

Prevention

Preventive measures are limited but include reducing exposure to endemic areas, especially avoiding activities that disturb soil in these regions. There is currently no vaccine available for histoplasmosis.

Prognosis

With appropriate antifungal therapy, the prognosis for localized African histoplasmosis is generally good. However, disseminated disease can be fatal, especially in immunocompromised individuals, highlighting the importance of early diagnosis and treatment.

See Also

• Histoplasmosis
• Fungal infection
• Mycosis